Bright Minds Biosciences (DRUG) Operating Income (2023 - 2024)

Bright Minds Biosciences' (DRUG) quarterly Operating Income came in at $32422.2 in Q4 2024, up 102.62% YoY from $16001.4 in Q1 2024, and down 79.37% on a QoQ basis from $157133.8 in Q2 2024.

Bright Minds Biosciences (DRUG) Operating Income (2023 - 2024) Analysis & Trends

Bright Minds Biosciences (DRUG) has 2 years of Operating Income data on file, last reported at $32422.2 in Q4 2024.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Op. Inc (Qtr)
1 Vertex Pharmaceuticals 128.13 Bn 120.28 Bn 2.84 Bn 1.25 Bn
2 Regeneron Pharmaceuticals 112.33 Bn 104.33 Bn 3.93 Bn 1.29 Bn
3 Argenx Se 53.24 Bn 48.05 Bn 1.41 Bn 493.00 Mn
4 Revolution Medicines 43.64 Bn 43.64 Bn - -505.13 Mn
5 BeOne Medicines 39.27 Bn 34.17 Bn 1.53 Bn 325.05 Mn
6 MindWalk Holdings 35.32 Bn 35.31 Bn 1.82 Bn -3,158.03
7 Royalty Pharma 33.72 Bn 35.84 Bn - 133.12 Mn
8 Alnylam Pharmaceuticals 30.58 Bn 27.27 Bn 992.69 Mn 231.44 Mn
9 Insmed 27.01 Bn 25.85 Bn 358.27 Mn -1.55 Mn
10 Bright Minds Biosciences 733.05 Mn 733.05 Mn - -

Historic Data

Download Data
DateValue
Dec 31, 2024 32,422.24
Jun 30, 2024 157,133.80
Dec 31, 2023 -1.24 Mn
Jun 30, 2023 -1.09 Mn